After a long and pitfall-strewn campaign, Iovance Biotherapeutics, Inc. has finally scored US accelerated approval of its T-cell therapy lifileucel for certain melanoma patients. The company’s share price rose by 33% to $12.14 after the close on 16 February on the NASDAQ, presumably on investors’ sheer relief.
Key Takeaways
- Iovance’s tumor infiltrating lymphocyte (TIL) therapy lifileucel has been approved in the US as Amtagvi
The battle is not strictly over yet. The company’s ongoing confirmatory trial, which sees the tumor-infiltrating lymphocyte (TIL) therapy, now...
